Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | DBH | P09172 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28012977 | 0.83 | KCNH2 (0.40) | CYP11B1CYP11B2MAPK1HTTSMN1; SMN2 | |
| SCHEMBL2510755 | 0.78 | SLC6A2 (0.37) | CYP11B1CYP11B2MAPK1HTTSMN1; SMN2 | |
| SCHEMBL2512773 | 0.72 | HTR6 (0.44) | MAPK1HTTSMN1; SMN2KCNH2KMT2A | |
| SCHEMBL27963398 | 0.71 | KCNH2 (0.63) | SMN1; SMN2KCNH2KMT2AALDH1A1LMNA | |
| SCHEMBL13187206 | 0.64 | ALOX5AP (0.69) | KCNH2KMT2ASLC6A3ALDH1A1ALOX5AP | |
| SCHEMBL10248963 | 0.62 | POLB (0.49) | HTTSMN1; SMN2KMT2ASLC6A2SLC6A3 | |
| SCHEMBL13800892 | 0.62 | KCNH2 (0.50) | MAPK1HTTSMN1; SMN2KCNH2KMT2A | |
| SCHEMBL22185256 | 0.61 | CYP11B1 (0.45) | CYP11B1CYP11B2MAPK1HTTSMN1; SMN2 | |
| SCHEMBL18925230 | 0.61 | NOTUM (0.55) | KMT2ARAB9AMEN1 | |
| SCHEMBL5983769 | 0.60 | KCNH2 (0.43) | CYP11B1CYP11B2MAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399444-B2 | Bicyclic imidazole as DP1 receptor antagonists | GlaxoSmithKline Intellectual Property Development Ltd. (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399444-B2 | Bicyclic imidazole as DP1 receptor antagonists | GlaxoSmithKline Intellectual Property Development Ltd. (GB) | 2013-03-19 | — | — | US | disclosed |
| US-8399444-B2 | Bicyclic imidazole as DP1 receptor antagonists | GlaxoSmithKline Intellectual Property Development Ltd. (GB) | 2013-03-19 | — | — | US | disclosed |
| EP-2373628-B1 | Bicyclic imidazole derivatives | GLAXO GROUP LTD (GB) | 2013-01-16 | — | — | EP | disclosed |
| EP-2373628-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2011-10-12 | — | — | EP | disclosed |
| US-20110245310-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2011-10-06 | — | — | US | disclosed |
| US-20110245310-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2011-10-06 | — | — | US | disclosed |
| US-20110245310-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2011-10-06 | — | — | US | disclosed |
| WO-2010070021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245310-A1 | Novel Compounds | HRH1, CMA1, HRH4 | CYP11B1 84/4885CYP11B2 88/4885MAPK1 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.